Section
This study demonstrates the long-term effectiveness and safety of autologous gene therapy for treating ADA deficiency, showing sustained immune function and minimal adverse effects over a median follow-up of 7.5 years.
Over the past two decades, advances in therapy have doubled the median survival of multiple myeloma patients, transforming this once devastating cancer into a more manageable disease through targeted drugs and immune therapies.
Recent clinical trials report encouraging tumor shrinkage with KRAS G12D inhibitor VS-7375, significant progression-free survival benefit in soft tissue sarcoma with ozekibart, and a novel gene therapy acquisition targeting wet AMD.
This study identifies specific T-cell receptor clonotypes associated with aggressive subtypes and poorer survival in mycosis fungoides and Sézary syndrome, supporting TCR sequencing as a tool for refined risk stratification in cutaneous T-c
This randomized trial demonstrates that eltrombopag significantly improves sustained platelet response in children with newly diagnosed ITP, offering a potential early intervention option.
This study highlights the prognostic significance of tumor Ki-67 changes during neoadjuvant treatment, offering potential for improved risk stratification and personalized therapy in breast cancer patients.
A restrictive treatment initiation approach in CLL, endorsed by the Brazilian Group of CLL, identifies patients with higher risk more accurately and spares low-risk patients from unnecessary therapy, showing superior prognostic stratificati
The IFM2017-03 phase 3 trial demonstrates that a dexamethasone-sparing regimen combining daratumumab with lenalidomide markedly improves progression-free survival in frail elderly multiple myeloma patients, without increasing serious advers
This study reveals that clonal hematopoiesis of indeterminate potential (CHIP) in adults aged 70+ does not increase cardiovascular risk but is associated with heightened bleeding risk. Aspirin showed no additional benefits or harms for thos
The TRIMM-2 study reveals that talquetamab plus daratumumab yields high response rates and durable disease control in relapsed/refractory multiple myeloma with manageable safety, offering a novel combination strategy for heavily pretreated
A retrospective study of 88 patients with genetically confirmed VEXAS syndrome reveals that azacitidine improves inflammatory symptoms, cytopenias, and reduces UBA1 mutant clone burden with an acceptable safety profile, supporting its use a
Loss of the tumor suppressor BAP1 characterizes a unique subtype of TP53-mutated de novo acute myeloid leukemia (AML), correlating with poorer prognosis and erythroid lineage priming, while revealing vulnerability to BCL-xL inhibition as a
This study characterizes UBA1 mutation effects in VEXAS syndrome and identifies UBA6 as a compensatory enzyme and promising therapeutic target, highlighting selective inhibition to combat mutant hematopoietic clones.
This study reveals that VEXAS syndrome-associated anemia results from a mosaic erythroblastopenia due to selective UBA1 mutations in early erythroid precursors, advancing understanding of its pathophysiology and therapeutic implications.
Reprogramming glutamine metabolism via Asct2 transporter expression improves BCMA-CAR T cell fitness, proliferation, and anti-myeloma efficacy under glutamine-limited conditions, offering a promising strategy to overcome metabolic immune ev
A response-adapted trial of daratumumab monotherapy in elderly newly diagnosed multiple myeloma reveals key biomarkers—CD38 expression, plasma cell phenotype, and immune microenvironment—that predict treatment sensitivity and inform therape
A comprehensive genomic analysis of Epstein-Barr virus (EBV) reveals distinct single nucleotide and structural variations linked to various human diseases, especially hematological malignancies, highlighting viral mechanisms underlying path
The POLARIX trial demonstrates superior progression-free survival with Pola-R-CHP in untreated DLBCL, highlighting the utility of patient-reported outcomes alongside clinician-reported adverse events to capture symptom burden and quality of
This article explores how genomic features differentiate stable from progressive asymptomatic Waldenström macroglobulinemia and IgM-MGUS, highlighting mutation burdens, specific gene alterations, and aneuploidy as prognostic markers for dis
A large genome-wide analysis identifies multiple genetic loci influencing MPN subtypes and reveals a female-specific variant at CDH22/CD40, enhancing understanding of disease heterogeneity and potential for personalized risk stratification.
